Episode Details
Back to Episodes
Marea Therapeutics today announced acceptance of a late-breaker at #EASCongress2025 for its ANGPTL4 inhibitor - believed to be the first ever clinical data presented for this lipid lowering target
Published 1 year, 5 months ago
Description
CEO Josh Lehrer and CSO Ethan Weiss describe the biology of the target and highlight the topline data, which was first announced at #JPM25. Plus, details on a new program targeting acromegaly.